MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo boost.

Could there be a third big pharma acquisition this week? MSD is rumoured to be in talks to buy Revolution Medicines in a deal that could be worth up to $32 billion. The chatter – first reported by the ...

On September 12, 2025, EPA released a proposal to permanently remove program obligations for 46 source categories of the GHGRP in accordance with President Trump's Executive Order 14192, "Unleashing ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...